You May Get Paid for Your Condition or Injury!

ABOUT INVOKANA

Invokana (canagliflozin) is a class of type 2 diabetes treatments called sodium-glucose co-transporter 2 (SGLT2) inhibitors that Johnson and Johnson brought to market in 2013. This class of medication works to treat Type 2 diabetes by stopping glucose (sugar) from being reabsorbed into the blood in the kidneys. Invokana stops the re-absorption of glucose by inhibiting a protein in the kidneys called SGLT2: a protein that normally functions to reabsorb 90 percent of glucose in the kidneys. When SGLT2 is inhibited, rather than reabsorbing the glucose, the kidney secretes the glucose and it leaves the body during urination: the result is lowered levels of glucose in the blood. Invokana, and other SGLT2 inhibitors, may lead to a serious condition called diabetic ketoacidosis (DKA). DKA occurs when the body cannot use glucose for fuel because there is too little or no insulin available; to compensate the body breaks down fat for fuel, which produces blood acids called ketones that can build up in the body as waste that can then become toxic. If gone untreated DKA can be fatal. If you or a loved one has taken Invokana and has experienced DKA, or is showing symptoms, you could be eligible for financial compensation.

Signs & Symptoms

Diabetic ketoacidosis (DKA) is a considered a medical emergency. If you or a loved one is has taken Invokana, or other SGLT2 Inhibitor and is experiencing the following symptoms please seek medical attention immediately. Signs and symptoms of DKA are: confusion or trouble focusing, difficulty breathing, aching muscles or muscle stiffness, unusual fatigue or sleepiness, vomiting and nausea, frequent urination, thirst that lasts for a day or more, flushed face, stomach pain and fruity-smelling breath or odor. Invokana and SGLT2 inhibitors can also cause bone fracture, decreased bone mineral density, kidney failure, heart attack, increased ketone levels and other complications. The FDA has received about 20 reports of ketoacidosis in patients treated with SGLT2 inhibitors from March 2013 to June 2014, and continues to receive reports of DKA connected to these drugs.

Take Action

If you are taking Invokana or an SGLT2 inhibitor and are experiencing any of the signs and symptoms listed above, or have been hospitalized for DKA while taking Invokana or other SGLT2 Inhibitor, you could be eligible for compensation for the hospital bills, expenses and pain that you have endured. Let Lawsuit Winning help you find legal help to pursue litigation and receive the financial compensation you deserve - – complete the free and easy claim review form today.